Hyperlipidemia of chronic renal failure

Blood Purification

Volumn 12, Issue 1, 1994, Pages 60-67

  Kaysen, George A ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Departments of Veterans Affairs Northern California System of Clinics ^*  (United States)

Author keywords

Apolipoproteins; CAPD; Dialysis; HDL; LCAT; Lipoprotein; Remnant particles VLDL; Uremia

Indexed keywords

APOLIPOPROTEIN; APOLIPOPROTEIN A1; APOLIPOPROTEIN A2; APOLIPOPROTEIN B; APOLIPOPROTEIN C3; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERMEDIATE DENSITY LIPOPROTEIN; LIPOPROTEIN; LIPOPROTEIN LIPASE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PHOSPHATIDYLCHOLINE STEROL ACYLTRANSFERASE; POLYUNSATURATED FATTY ACID; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

CHRONIC KIDNEY FAILURE; CONFERENCE PAPER; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; DIALYSIS; ERYTHROCYTE MEMBRANE; GLUCOSE ABSORPTION; HYPERLIPIDEMIA; HYPERLIPOPROTEINEMIA TYPE 1; INSULIN RESISTANCE; LEUKOCYTE; LIPID BILAYER; LIPOPROTEIN METABOLISM; MEMBRANE FLUIDITY; PRIORITY JOURNAL; SECONDARY HYPERPARATHYROIDISM; TRIACYLGLYCEROL BLOOD LEVEL; UREMIA;

ANTILIPEMIC AGENTS; CARDIOVASCULAR DISEASES; HEMODYNAMIC PROCESSES; HUMANS; HYPERLIPIDEMIAS; HYPERTRIGLYCERIDEMIA; KIDNEY FAILURE, CHRONIC; LIPOPROTEINS; MEMBRANE LIPIDS; OXIDATION-REDUCTION; PERITONEAL DIALYSIS, CONTINUOUS AMBULATORY; PHOSPHATIDYLCHOLINE-STEROL O-ACYLTRANSFERASE; RENAL DIALYSIS;

EID: 0028128602     PISSN: 02535068     EISSN: 14219735     Source Type: Journal    
DOI: 10.1159/000170146     Document Type: Article

References (73)

1. Bagdade JD, Porte D, Bierman EL: Hypertriglyceridaemia. A metabolic consequence of chronic renal failure. N Engl J Med 1968;279:181-185.
2. Attman PO, Alaupovie P: Lipid abnormalities in chronic renal insufficiency. Kidney Int 1991;39:S-16-S- 23.
3. Rapoport J, Aviram M, Chaimovitz C, Brook JG: Defective high-density lipoprotein composition in patients on chronic hemodialysis: A possible mechanism for accelerated atherosclerosis. N Engl J Med 1978;299: 1326-1329.
4. Goldberg AP, Harter HR, Patsch W, Schechtman KB, Province M, Werts C, Kuisk I, McCratc MM, Schonfeld G: Racial differences in plasma high-density lipoprotein in patients receiving hemodialysis: A possible mechanism for accelerated atherosclerosis in white men. N Engl J Med 1983;308:1245-1252.
5. Zacchello G, Pagnan A, Sidran MP, Ziron L, Braggion M, Pavanello L, Facchin P: Further definition of lip- id-lipoprotein abnormalities in children with various degrees of chronic renal insufficiency, Pediatr Res 1987;21:462-465.
6. Attman PO, Alaupovic P, Gustafson A: Serum apolipoprotein profile of patients with chronic renal failure. Kidney Int 1987;32:368-375.
7. Fuh MMT, Lee CM, Jeng CY, Shen DC, Shieh SM, Reaven GM, Chen YDI: Effect of chronic renal failure on high-dcnsity lipoprotein kinetics. Kidney Int 1990;37:1295-1300.
8. McLeod R, Reeve CE, Frohlich J: Plasma lipoprotein and lecithin: cholesterol acyltransferase distribution in patients on dialysis. Kidney Int 1964;25:683-688.
9. Atger V, Duval F, Frommherz K, Drüeke T, Lacour B: Anomalies in composition of uremic lipoproteins isolated by gradient ultracentrifugation: Relative enrichment of HDL in apolipoprotein C-III at the expense of apolipoprotein A-I. Atherosclerosis 1988;74:75-83.
10. Tan MH, Barry LE: Changes in the composition of plasma lipoproteins in the chronic uremic rat. Atherosclerosis 1990;85:139-150.
11. Ron D, Oren I, Aviram M, Better OS, Brook JG: Accumulation of lipoprotein remnants in patients with chronic renal failure. Atherosclerosis 1983;46:67-75.
12. Drüeke T, Lacour B, Roullet JB, Funk-Brentano JL: Recent advances in factors that alter lipid metabolism in chronic renal failure. Kidney Int 1983;24:S-134-S-138.
13. Sun X, Jones H Jr, Joles JA, van Tol A, Kaysen GA: Apolipoprotein gene expression in the analbuminemic ral and in the rat with Heymann nephritis. Am J Physiol 1992;262: F755-F761.
14. Kostner GM, Avogaro P, Cazzolato G et al: Lipoprotein Lp(a) and the risk for myocardial infarction. Atherosclerosis 1981;38:51-61.
15. Utermann G: The mysteries of lipo- protein(a). Science 1989;246:904-910.
16. Boerwinkle E, Menzel HJ, Kraft HG, Utermann G: Genetics of the quantitative Lp(a) lipoprotein trait. III. Contribution of Lp(a) glycoprotein phenotypes to normal lipid variation. Hum Genet 1989;82:73- 78.
17. Gavish D, Azrolan N, Breslow J: Plasma Lp(a) concentration is inversely correlated with the ratio of kringle IV/kringle V encoding domains in the apo(a) gene. J Clin Invest 1989;84:2021-2027.
18. Karádi I, Romies L, Pálos G, et al: Lp(a) lipoprotein concentration in serum of patients with heavy proteinuria of different origin. Clin Chem 1989;35:2121-2123.
19. Guillausseau PJ, Peynet J, Chanson P, Legrand A, Altman JJ, Poupon J, N’Guyen M, Rousselet F, Lubetzki J: Lipoprotein (a) in diabetic patients with and without chronic renal failure. Diabetes Care 1992; 15: 976-979.
20. Chan MK, Varghcse Z, Persaud JW, Vaillod RA, Moorhead JF: Hyperlipidemia in patients on maintenance hemo- and peritoneal dialysis: The relative pathogenetic roles of triglyceride production and triglyceride removal. Clin Nephrol 1982; 17:183-190.
21. Morgenroth J, Levy RI, Fredrickson DS: The biochemical, clinical, and genetic features of type III hyperlipoproteinemia. Ann Intern Med 1975;82:158-174.
22. Chung BH, Segrest JP, Smith K, Griffin FM, Brouillette CG: Lipolytic surface remnants of triglyccride- rich lipoproteins are cytotoxic to macrophages but not in the presence of high density lipoprotein A possible mechanism of atherogenesis? J Clin Invest 1989;83:1363-1374.
23. Schaefer EJ, Levy RI: Pathogenesis of management of lipoprotein disorders. N Engl Med 1985;312:1300- 1310.
24. Crawford GA, Mahony JF, Stewart JH: Impaired lipoprotein lipase activation by uraemic and post-transplant sera. Clin Sci 1981;60:73-78.
25. Verschoor L, Baggen RGA, Jansen H., Birkenhäger JC: Different causes for hypertriglyceridemia in male and female patients with chronic renal failure? J Clin Endocrinol Metab 1983;56:592-594.
26. Tall AR: Plasma high density lipoproteins: Metabolism and relationship to atherogenesis. J Clin Invest 1990;86:379-384.
27. Eisenberg S: High density lipoprotein metabolism. J Lip Res 1984;25:1017.
28. Bories PC, Subbaiah PV, Bagdade JD: Lecithinxholesterol acyltrans- ferase activity in dialyzed chronic uremic patients. Nephron 1982;32: 22-27.
29. Mitchell ME: Carnitine metabolism in human subjects. I. Normal metabolism. Am J Clin Nutr 1978;31: 293.
30. Guamieri GF, Ranieri F, Toigo G, Vasile A, Ciman M, Rizzoli V, Mo- racchiello M, Campanacci L: Lipid- lowering effect of carnitine in chronically uremic patients treated with maintenance hemodialysis. Am J Clin Nutr 1980;33:1489-1492.
31. Bartel LL, Hussey JL, Shrago E: Effect of dialysis on serum carnitine, free fatty acids, and triglyceride levels in man and the rat. Metabolism 1982;31:944-947.
32. Golperr TA, Wolfson M, Ahmad S, Hirschberg R, Kurtin P, Katz LA, Nocora R, Ashbrook D, Kopple JD: Multicenter trial of L-carniline in maintenance hemodialysis patients. I. Carnitine concentrations and lipid effects. Kidney Int 1990;38:904-911.
33. Lacour B, Roullet JB, Liagre AM, Jorgetti V, Beyne P, Dubost C, Drüekc T: Serum lipoprotein disturbances in primary and secondary hyperparathyroidism and effects of parathyroidectomy. Am J Kidney Dis 1986;8:422-429.
34. Drüeke T, Lacour B: Parathyroid hormone and hyperlipidemia of uremia. Contrib Nephrol. Basel, Karger, 1985, vol 49. pp 12-19.
35. Roxe DM, del Greco F, Hughes J, Krumlovsky F, Ghantous W, Ivanovich P, Quintanilla A, Salkin M, Stone NJ, Reins M: Hemodialysis vs. peritoneal dialysis: Results of a 3-year prospective controlled study. Kidney Int 1981;19:341-348.
36. Jüngst D, Caselmann WH, Kut- schera P, Weisweiler P: Relation of hyperlipidemia in serum and loss of high density lipoproteins in urine in the nephrotic syndrome. Clin Chin Acta 1987; 168:159-167.
37. Kagan A, Bar-Khayim Y, Schafer Z, Fainaru M: Kinetics of peritoneal protein loss during CAPD: II. Lipoprotein leakage and its impact on plasma lipid levels. Kidney Int 1990;37:980-990.
38. Dibble JB, Young GA, Hobson SM, Brownjohn AM: Amino acid based continuous ambulatory peritoneal dialysis (CAPD) fluid over twelve weeks: Effects on carbohydrate and lipid metabolism. Periton Dial Int 1990;10:71-77.
39. Morin RJ, Srikantaiah MV, Woodley Z, Davidson WD: Effect of hemodialysis with acetate vs. bicarbonate on plasma lipid and lipoprotein levels in uremic patients. J Dial 1980;4:9-20.
40. Kasiske B, Umen AJ: Persistent hy- perlipidemia in renal transplant patients. Medicine 1987;66:309-316.
41. Kobayashi N, Okubo M, Marumo F, Uchida H, Endo T, Nakamura H: De novo development of hypercholesterolemia and elevated high-den- sity lipoprotein cholesterol apoprotein A-I ratio in patients with chronic renal failure following kid- ncv transplantation. Nephron 1983; 35:237-240.
42. Rubiés-Prat J, Romero R, Chacón P, Masdeu S, Griño J, Caralps A: Apoprotein A and apoprotein B in patients with chronic renal failure undergoing hemodialysis and in renal graft recipients. Nephron 1983; 35:171-174.
43. Lowrie EG, Lazarus JM, Mocelin AJ, Bailey GL, Hampers CL, Wilson RE, Merrill JP: Survival of patients undergoing hemodialysis and renal transplantation. N Engl J Med 1973; 288:8633-867.
44. Lowry RP, Soltys G, Peiers L, Mangel R, Snidemian AD: Type II hyperlipoproteinemia, hype rapobetali- poprotcinemia, and hyperalphalipo- proteinemia following renal transplantation: Implication for atherogenic risk. Transplantation Proc 1987; 19:3426-3430.
45. Hodel K, Mordasini RC, Brunner FP, Thiel G: Cyclosporin A und Hy- perlipidämie nach Nierentransplan- tation. Schweiz Med Woschr 1986; 116:885-888.
46. Jevnikar AM, Petrie R, Holub BJ, Philbrick DJ, Clark WF: Effect of cyclosporine on plasma lipids and modification with dietary fish oil. T ransplantation 1988;46:722-725.
47. Becker DM, Chamberlain B, Swank R, Hegewald MG, Girardet R, Baughman KL, Kwiterovich PO, Person TA, Ettinger WH, Renlund D: Relationship between corticosteroid exposure and plasma lipid levels in heart transplant recipients. Am J Med 1988;85:632-638.
48. Peuchant E, Salles C, Vallot C, Wone C, Jensen R: Increase of erythrocyte resistance to hemolysis and modification of membrane lipids induced by hemodialysis. Clin Chim Acta 1988;178:271-282.
49. Girelli D, Lupo A, Trevisan MT, Olivieri O, Bemich P, Zorzan P, Bassi A, Stanzial AM, Ferrari S, Corrocher R: Red blood cell susceptibility to lipid peroxidation, membrane lipid composition, and anti- toxidant enzymes in continuous ambulatory peritoneal dialysis patients. Periton Dial Int 1992;12:205-210.
50. Dasgupta A, Kenny MA, Ahmad S: Abnormal fatty acid profile in chronic hemodialysis patients: possible deficiency of essential fatty acids. Clin Physiol Biochem 1990;8: 238-243.
51. Peuchant E, Motta C, Salles C, Clere M: A compensatory mechanism improving red cell membrane fludity in hemodialyzed patients. Clin Chim Acta 1990;190:57-66.
52. Masuda M, Komiyama Y, Murakami T, Murata K: Decrease of polymorphonuclear leukocyte membrane fluidity in uremic patients on hemodialysis. Nephron 1990;54: 36-41.
53. Dasgupta A, Hussain S, Ahmad S: Increased lipid peroxidation in patients on maintenance hemodialysis. Nephron 1992;60:56-59.
54. Linder A, Charra B, Sherrard D, et al: Accelerated atherosclerosis in prolonged maintenance hemodialysis. N Engl J Med 1974;290:697- 701.
55. Burton BT, Krueger KK, Gryan FA Jr: National Registry of long-term dialysis patients. JAMA 1971;218: 718-722.
56. Burrell DW, Antignani A, Gold- wasser P, Mittman N, Fein PA, Slater PA, Gan A, Avrani MM: Lipid abnormalities in black renal patients. NY State J Med 1991;91: 192-196.
57. Kindler J, Sieberth HG, Hahn R, Glöckner WM, Valaho M, Pelzer R: Does atherosclerosis caused by dialysis limit this treatment? Proc EDTA 1982;19:168-174.
58. Schmitz PG, Kasiske BL, O’Donnell MP, Keane WF: Lipids and progressive renal injury. Semin Nephrol 1989;9:354-369.
59. Wellman KF, Volk BW: Renal changes in experimental hyper-cho- lesterolemia in normal and subdiabetic rabbits. I. Short term studies. Lab Invest 1970;22:36-48.
60. Drevon CA, Hoving T: The effects of cholesterol/fat feeding on lipid levels and morphological structures in liver, kidney and spleen in guinea pigs. Acta Pathol Micro Immunol Scand 1977;85:1-18.
61. Al-Shcbeb T, Frohlich J, Magil AB: Glomerular disease in hypercholes- terolemie guinea pigs: A pathogenetic study. Kidnev Int 1988;33:498- 507.
62. Schmitz PG, O’Donnell MP, Ka- siske BL, Keane WF: Dietary induced hypercholesterolemia elevates glomerular capillary pressure. Kidney Int 1989;35:473A.
63. Kaplan R, Aynedjian HS, Bank N, Schlöndorff D: Cholesterol feeding causes renal vasoconstriction via oxidized lipoprotein activation of thromboxane. Kidney Int 1990;37: 371 A.
64. Diamond JR, Kamovsky MJ: Exacerbation of chronic aminonucleo- side nephrosis by dietary cholesterol supplementation. Kidney Int 1987; 31:671-677.
65. Hanchak NA, Kamovsky MJ, Diamond JR: Cholestyramine lowers acute and recurrent proteinuria in chronic puromycin aminonucleo- side nephrosis. Kidney Int 1988;33: 376A.
66. Pesek-Diamond I, Ding G, Frye J, Diamond JR: Macrophages mediate adverse effects of cholesterol feeding in experimental nephrosis. Am J Physiol 1992;263:F775-F783.
67. Larger DJ, Rosenberg BF, Shapiro H, Bernstein J: Lecithin cholesterol acyltransfcrase deficiency: Ultra- structural examination of sequential renal biopsies. Modern Pathol 1991; 4:331-335.
68. Chan MK: Sustained-release bezafi- brate corrects lipid abnormalities in patients on continuous ambulatory peritoneal dialysis. Nephron 1990; 56:56-61.
69. Golper TA: Therapy for uremic hy- perlipidemia. Nephron 1984;38: 217-225.
70. Di Paolo B, Del Rosso G, Catucci G, Vonino V, Terenzio MG, Bonomini M, Suriani K, Albertazzi A: Therapeutic effects of simvastatin on hy- perlipidaemia in CAPD patients. ASAIO Trans 1990;36:M578- M580.
71. Kirsten R, Heintz B, Nelson K, Ore- mek G: Reduction of hyperlipid- emia with 3-sn-polyenylphosphati- dylcholine in dialysis patients. Int J of Clin Pharmacol Ther Toxicol 1989;27:129-134.
72. Chan MK: Gemfibrozil improves abnormalities of lipid metabolism in patients on continuous ambulatory peritoneal dialysis: The role of post- heparin lipases in the metabolism of high-density lipoprotein subfractions. Metabolism 1989;38:939- 945.
73. Deuber HJ, Schultz W: Reduced lipid concentrations during four years of dialysis with low molecular weight heparin. Kidney Int 1991; 40: 496-500.